Zengin, MehmetZergeroglu, SemaOkcu, OguzhanBenek, Suat2025-01-212025-01-2120212211-34282211-3436https://doi.org/10.1007/s13402-020-00579-5https://hdl.handle.net/20.500.12587/25242Background Immune responses have long been an area of interest in cancer research. In this study, the effects of programmed cell death-1 (PD-1) and its ligand (PD-L2) on the prognosis of colorectal cancer (CRC) were investigated. Methods Primary tumour specimens of stage III CRC patients operated between 2002 and 2013 were assessed for PD-1 and PD-L2 expression and various clinicopathological and prognostic factors. Results We observed a significant relationship between poor prognostic factors and PD-1/PD-L2 expression. These biomarkers were also found to serve as independent risk factors for LIR and MSI. In univariate analysis, relapse-free survival (RFS) and overall survival (OS) rates were found to be poor in PD-1 and PD-L2 positive patients. In multivariate analysis, these biomarkers were found to serve as independent poor prognostic factors for RFS and OS. Conclusions Our data indicate that PD-1 and PD-L2 may serve as independent prognostic survival parameters for CRC patients and may be employed for the design of targeted theapies.eninfo:eu-repo/semantics/closedAccessColorectal cancer; PD-1; PDL-2; Prognostic biomarkers; Stage IIIArticle44242343210.1007/s13402-020-00579-52-s2.0-8510002170433469839Q1WOS:000608965100003Q1